# Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:

> **NCT06322238** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 66 (estimated)

## Conditions studied

- Pharmacogenomic Drug Interaction
- Side Effect of Drug
- Ineffective Drug Action
- Drug Metabolism, Poor, CYP2D6-Related
- Drug Metabolism, Poor, CYP2C19-Related

## Interventions

- **DIAGNOSTIC_TEST:** PGx panel test

## Key facts

- **NCT ID:** NCT06322238
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2026-12
- **Final completion:** 2027-04
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06322238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06322238, "Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06322238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*